ARAY

Company Overview — What Does ACCURAY INC Do?

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the Americas, Europe, the Middle East, India, Africa, Japan, China, and rest of the Asia Pacific region. It offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body, such as prostate, lung, brain, spine, liver, pancreas, and kidney. The company also provides the TomoTherapy System, including the Radixact System, which consists of an integrated radiation therapy system designed for the treatment of a range of cancer types. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Sunnyvale, California. ACCURAY INC (ARAY) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Suzanne C. Winter and employs approximately 1,040 people, headquartered in Sunnyvale, Wisconsin. With a market capitalization of $46M, ARAY is one of the notable companies in the Healthcare sector.

ACCURAY INC (ARAY) Stock Rating — Avoid (April 2026)

As of April 2026, ACCURAY INC receives a Avoid rating with a composite score of 27.0/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.ARAY ranks #4,269 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, ACCURAY INC ranks #773 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ARAY Stock Price and 52-Week Range

ACCURAY INC (ARAY) currently trades at $0.39. The stock lost $0.03 (7.6%) in the most recent trading session. The 52-week high for ARAY is $2.10, which means the stock is currently trading -81.5% from its annual peak. The 52-week low is $0.33, putting the stock 17.8% above its annual trough. Recent trading volume was 1.3M shares, reflecting moderate market activity.

Is ARAY Overvalued or Undervalued? — Valuation Analysis

ACCURAY INC (ARAY) carries a value factor score of 24/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.84x, versus the sector average of 2.75x. The price-to-sales ratio is 0.10x, compared to 1.66x for the average Healthcare stock.

At current multiples, ACCURAY INC trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

ACCURAY INC Profitability — ROE, Margins, and Quality Score

ACCURAY INC (ARAY) earns a quality factor score of 34/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -64.0%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -7.6% versus the sector average of -33.1%.

On a margin basis, ACCURAY INC reports gross margins of 28.9%, compared to 71.5% for the sector. The operating margin is -4.6% (sector: -66.1%). Net profit margin stands at -8.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 0.7% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ARAY Debt, Balance Sheet, and Financial Health

ACCURAY INC has a debt-to-equity ratio of 254.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.47x, suggesting adequate working capital coverage. Total debt on the balance sheet is $136M.

ARAY has a beta of 1.43, meaning it is more volatile than the broader market — a $10,000 investment in ARAY would be expected to move 43.3% more than the S&P 500 on any given day. The stability factor score for ACCURAY INC is 26/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

ACCURAY INC Revenue and Earnings History — Quarterly Trend

In TTM 2026, ACCURAY INC reported revenue of $426M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-34M. Gross margin was 28.9%. Operating income came in at $-17M.

In Q2 2026, ACCURAY INC reported revenue of $102M and earnings per share (EPS) of $-0.11. Net income for the quarter was $-14M. Gross margin was 23.5%. Revenue grew -12.0% year-over-year compared to Q2 2025. Operating income came in at $-12M.

In Q1 2026, ACCURAY INC reported revenue of $94M and earnings per share (EPS) of $-0.18. Net income for the quarter was $-22M. Gross margin was 28.3%. Revenue grew -7.5% year-over-year compared to Q1 2025. Operating income came in at $-11M.

In FY 2025, ACCURAY INC reported revenue of $459M and earnings per share (EPS) of $-0.02. Net income for the quarter was $-2M. Gross margin was 32.0%. Revenue grew 2.7% year-over-year compared to FY 2024. Operating income came in at $8M.

Over the past 8 quarters, ACCURAY INC has experienced revenue contraction from $447M to $426M. Investors analyzing ARAY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ARAY Dividend Yield and Income Analysis

ACCURAY INC (ARAY) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ARAY Momentum and Technical Analysis Profile

ACCURAY INC (ARAY) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 33/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 49/100 reflects moderate short selling activity.

ARAY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, ACCURAY INC (ARAY) ranks #773 out of 838 stocks based on the Blank Capital composite score. This places ARAY in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ARAY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ARAY vs S&P 500 (SPY) comparison to assess how ACCURAY INC stacks up against the broader market across all factor dimensions.

ARAY Next Earnings Date

No upcoming earnings date has been announced for ACCURAY INC (ARAY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ARAY? — Investment Thesis Summary

The quantitative profile for ACCURAY INC suggests caution. The quality score of 34/100 flags below-average profitability. The value score of 24/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 26/100) increases portfolio risk.

In summary, ACCURAY INC (ARAY) earns a Avoid rating with a composite score of 27.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ARAY stock.

Related Resources for ARAY Investors

Explore more research and tools: ARAY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ARAY head-to-head with peers: ARAY vs AZN, ARAY vs SLGL, ARAY vs VMD.